{"transactions":[{"id":4093,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2672,"kind":"person","name":"Melincoff Gwen A","position":1,"cik":"0001614890","reported_name":"Melincoff Gwen A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-09-04T10:00:23.000Z","date":"2026-09-03","kind":"grant","planned":false,"acquired":true,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of the Isuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant."}],"balance_after":8500,"derivative":{"underlying":"Common Stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001614890-26-000002","document":"form4-09042026_060915.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1614890/000161489026000002/form4-09042026_060915.xml","form_type":"4"}},{"id":4092,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2672,"kind":"person","name":"Melincoff Gwen A","position":1,"cik":"0001614890","reported_name":"Melincoff Gwen A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2026-09-04T10:00:23.000Z","date":"2026-09-03","kind":"grant","planned":false,"acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options vest in 12 equal quarterly installments commencing upon the date of grant."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include (i) options to purchase 40,000 shares of common stock at an exercise price equal to $3.55 per share that expire on January 20, 2030, (ii) options to purchase 50,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032, (iii) options to purchase 61,676 shares of common stock at an exercise price equal to $1.66 per share that expire on September 29, 2033 and (iv) options to purchase 15,000 shares of common stock at an exercise price equal to $1.64 per share that expire on September 3, 2035."}],"balance_after":17000,"derivative":{"exercise_price":2.59,"expiration_date":"2036-09-03","underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001614890-26-000002","document":"form4-09042026_060915.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1614890/000161489026000002/form4-09042026_060915.xml","form_type":"4"}},{"id":707441,"issuer":{"id":6943,"kind":"organization","name":"Gain Therapeutics, Inc."},"owners":[{"id":2672,"kind":"person","name":"Melincoff Gwen A","position":1,"cik":"0001614890","reported_name":"Melincoff Gwen A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-07-17T12:31:28.000Z","date":"2026-07-15","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in 12 equal monthly installments commencing on July 24, 2026, subject to the Reporting Person's continuous service through the applicable vesting date."}],"balance_after":25000,"derivative":{"exercise_price":1.68,"expiration_date":"2036-07-15","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001104659-26-084435","document":"tm2620629-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819411/000110465926084435/tm2620629-3_4seq1.xml","form_type":"4"}},{"id":1048616,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2672,"kind":"person","name":"Melincoff Gwen A","position":1,"cik":"0001614890","reported_name":"Melincoff Gwen A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2025-09-04T21:00:24.000Z","date":"2025-09-03","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Does not include (i) options to purchase 40,000 shares of common stock at an exercise price equal to $3.55 per share that expire on January 20, 2030, (ii) options to purchase 50,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032 and (iii) options to purchase 61,676 shares of common stock at an exercise price equal to $1.66 per share that expire on September 29, 2033."}],"balance_after":15000,"derivative":{"exercise_price":1.64,"expiration_date":"2035-09-03","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001415889-25-023706","document":"form4-09042025_050913.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000141588925023706/form4-09042025_050913.xml","form_type":"4"}},{"id":1048615,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2672,"kind":"person","name":"Melincoff Gwen A","position":1,"cik":"0001614890","reported_name":"Melincoff Gwen A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-04T21:00:24.000Z","date":"2025-09-03","kind":"grant","planned":false,"acquired":true,"shares":7500,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents restricted shares of common stock awarded to the Reporting Person under the Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended (the \"Plan\"). The restricted shares vest in 12 equal quarterly installments commencing\nupon the date of grant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued under the Plan must be registered in the name of a trustee."}],"balance_after":7500,"source":{"system":"sec-edgar","filing":"0001415889-25-023706","document":"form4-09042025_050913.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000141588925023706/form4-09042025_050913.xml","form_type":"4"}},{"id":1101983,"issuer":{"id":6943,"kind":"organization","name":"Gain Therapeutics, Inc."},"owners":[{"id":2672,"kind":"person","name":"Melincoff Gwen A","position":1,"cik":"0001614890","reported_name":"Melincoff Gwen A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-25T21:30:13.000Z","date":"2025-06-24","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in 12 equal monthly installments commencing on July 24, 2025, subject to the Reporting Person's continuous service through the applicable vesting date."}],"balance_after":15000,"derivative":{"exercise_price":1.79,"expiration_date":"2035-06-24","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001641172-25-016538","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819411/000164117225016538/ownership.xml","form_type":"4"}},{"id":1469119,"issuer":{"id":6943,"kind":"organization","name":"Gain Therapeutics, Inc."},"owners":[{"id":2672,"kind":"person","name":"Melincoff Gwen A","position":1,"cik":"0001614890","reported_name":"Melincoff Gwen A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-27T01:30:11.000Z","date":"2024-06-24","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in 12 equal monthly installments commencing on July 24, 2024, subject to the Reporting Person's continuous service through the applicable vesting date."}],"balance_after":15000,"derivative":{"exercise_price":1.29,"expiration_date":"2034-06-24","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001493152-24-025341","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819411/000149315224025341/ownership.xml","form_type":"4"}},{"id":1514045,"issuer":{"id":5169,"kind":"organization","name":"COLLEGIUM PHARMACEUTICAL, INC"},"owners":[{"id":2672,"kind":"person","name":"Melincoff Gwen A","position":1,"cik":"0001614890","reported_name":"Melincoff Gwen A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-16T23:23:27.000Z","date":"2024-05-16","kind":"grant","planned":false,"acquired":true,"shares":7693,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the grant of restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on May 16, 2025, subject to the director's continued service with the Issuer. The RSUs will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the Issuer, in shares of the Issuer's common stock."}],"balance_after":52468,"source":{"system":"sec-edgar","filing":"0001062993-24-010542","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1267565/000106299324010542/form4.xml","form_type":"4"}},{"id":1768754,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2672,"kind":"person","name":"Melincoff Gwen A","position":1,"cik":"0001614890","reported_name":"Melincoff Gwen A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2023-10-03T21:00:54.000Z","date":"2023-09-29","kind":"grant","planned":false,"acquired":true,"shares":61676,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant.  The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include (i) options to purchase 40,000 shares of common stock at an exercise price equal to $3.55 per share that expire on January 20, 2030 and (ii) options to purchase 50,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032."}],"balance_after":61676,"derivative":{"exercise_price":1.66,"expiration_date":"2033-09-29","underlying":"Common Stock","underlying_shares":61676},"source":{"system":"sec-edgar","filing":"0001415889-23-013902","document":"form4-10032023_051032.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000141588923013902/form4-10032023_051032.xml","form_type":"4"}},{"id":1844591,"issuer":{"id":6943,"kind":"organization","name":"Gain Therapeutics, Inc."},"owners":[{"id":2672,"kind":"person","name":"Melincoff Gwen A","position":1,"cik":"0001614890","reported_name":"Melincoff Gwen A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-26T20:38:09.000Z","date":"2023-06-23","kind":"grant","planned":false,"acquired":true,"shares":10500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in 12 equal monthly installments commencing on July 23, 2023, subject to the Reporting Person's continuous service through the applicable vesting date."}],"balance_after":10500,"derivative":{"exercise_price":4.5,"expiration_date":"2033-06-23","underlying":"Common Stock","underlying_shares":10500},"source":{"system":"sec-edgar","filing":"0001209191-23-039721","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819411/000120919123039721/doc4.xml","form_type":"4"}},{"id":1876465,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":2672,"kind":"person","name":"Melincoff Gwen A","position":1,"cik":"0001614890","reported_name":"Melincoff Gwen A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2023-05-26T22:30:12.000Z","date":"2023-05-26","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the Option shall vest on November 26, 2023, subject to the Reporting Person continuing to be a Service Provider through such date."}],"balance_after":10000,"derivative":{"exercise_price":5.25,"expiration_date":"2033-05-26","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-23-032696","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1484565/000120919123032696/doc4.xml","form_type":"4"}},{"id":1876464,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":2672,"kind":"person","name":"Melincoff Gwen A","position":1,"cik":"0001614890","reported_name":"Melincoff Gwen A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2023-05-26T22:30:12.000Z","date":"2023-05-25","kind":"grant","planned":false,"acquired":true,"shares":2666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the Option shall vest on the earlier of the twelve-month anniversary of May 25, 2023 or the day before the next annual stockholder meeting, subject to the Reporting Person continuing to be a Service Provider through such date."}],"balance_after":2666,"derivative":{"exercise_price":5.03,"expiration_date":"2033-05-25","underlying":"Common Stock","underlying_shares":2666},"source":{"system":"sec-edgar","filing":"0001209191-23-032696","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1484565/000120919123032696/doc4.xml","form_type":"4"}},{"id":1884327,"issuer":{"id":5169,"kind":"organization","name":"COLLEGIUM PHARMACEUTICAL, INC"},"owners":[{"id":2672,"kind":"person","name":"Melincoff Gwen A","position":1,"cik":"0001614890","reported_name":"Melincoff Gwen A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-19T20:38:45.000Z","date":"2023-05-18","kind":"grant","planned":false,"acquired":true,"shares":9792,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest on May 18, 2024, subject to the director's continued service with the issuer. The restricted stock units will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the issuer, in shares of the issuer's common stock."}],"balance_after":44775,"source":{"system":"sec-edgar","filing":"0001062993-23-011815","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1267565/000106299323011815/form4.xml","form_type":"4"}},{"id":2137046,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":2672,"kind":"person","name":"Melincoff Gwen A","position":1,"cik":"0001614890","reported_name":"Melincoff Gwen A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2022-10-14T22:30:42.000Z","date":"2022-06-01","kind":"grant","acquired":true,"shares":2666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The per share exercise price and number of shares subject to the option reflect the 1-for-15 reverse stock split effected August 26, 2022."},{"field":"shares","element":"transactionShares","label":"F1","text":"The per share exercise price and number of shares subject to the option reflect the 1-for-15 reverse stock split effected August 26, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the Option shall vest on the earlier of the twelve-month anniversary of June 1, 2022 or the day before the next annual stockholder meeting, subject to Reporting Person continuing to be a Service Provider through each such date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The per share exercise price and number of shares subject to the option reflect the 1-for-15 reverse stock split effected August 26, 2022."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The per share exercise price and number of shares subject to the option reflect the 1-for-15 reverse stock split effected August 26, 2022."}],"balance_after":2666,"derivative":{"exercise_price":2.55,"expiration_date":"2032-06-01","underlying":"Common Stock","underlying_shares":2666},"source":{"system":"sec-edgar","filing":"0001209191-22-053697","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1484565/000120919122053697/doc4.xml","form_type":"4"}},{"id":2152992,"issuer":{"id":6943,"kind":"organization","name":"Gain Therapeutics, Inc."},"owners":[{"id":2672,"kind":"person","name":"Melincoff Gwen A","position":1,"cik":"0001614890","reported_name":"Melincoff Gwen A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-09-22T20:09:23.000Z","date":"2022-09-20","kind":"grant","acquired":true,"shares":10500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests fully on the day before the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service as a director of the Issuer."}],"balance_after":10500,"derivative":{"exercise_price":3.5,"expiration_date":"2032-09-20","underlying":"Common Stock","underlying_shares":10500},"source":{"system":"sec-edgar","filing":"0001209191-22-051009","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819411/000120919122051009/doc4.xml","form_type":"4"}},{"id":2162614,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2672,"kind":"person","name":"Melincoff Gwen A","position":1,"cik":"0001614890","reported_name":"Melincoff Gwen A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2022-09-09T21:01:09.000Z","date":"2022-09-07","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include options to purchase 40,000 shares of common stock at an exercise price equal to $3.55 per share that expire on January 20, 2030."}],"balance_after":50000,"derivative":{"exercise_price":1.03,"expiration_date":"2032-09-07","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001104659-22-098944","document":"tm2225460-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000110465922098944/tm2225460-2_4seq1.xml","form_type":"4"}},{"id":2259747,"issuer":{"id":5169,"kind":"organization","name":"COLLEGIUM PHARMACEUTICAL, INC"},"owners":[{"id":2672,"kind":"person","name":"Melincoff Gwen A","position":1,"cik":"0001614890","reported_name":"Melincoff Gwen A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-23T21:42:31.000Z","date":"2022-05-19","kind":"grant","acquired":true,"shares":14035,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest on May 19, 2023, subject to the director's continued service with the issuer. The restricted stock units will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the issuer, in shares of the issuer's common stock."}],"balance_after":34983,"source":{"system":"sec-edgar","filing":"0001062993-22-013313","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1267565/000106299322013313/form4.xml","form_type":"4"}},{"id":2680885,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":2672,"kind":"person","name":"Melincoff Gwen A","position":1,"cik":"0001614890","reported_name":"Melincoff Gwen A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee stock option (right to buy)","published_at":"2021-06-04T20:31:55.000Z","date":"2021-06-01","kind":"grant","acquired":true,"shares":31862,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the Option shall vest on the earlier of the twelve-month anniversary of June 1, 2022 or the day before the next annual stockholder meeting, subject to Reporting Person continuing to be a Service Provider through each such date."}],"balance_after":31862,"derivative":{"exercise_price":1.02,"expiration_date":"2021-06-01","underlying":"Common Stock","underlying_shares":31862},"source":{"system":"sec-edgar","filing":"0000899243-21-022052","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1484565/000089924321022052/doc4.xml","form_type":"4"}},{"id":2698580,"issuer":{"id":5169,"kind":"organization","name":"COLLEGIUM PHARMACEUTICAL, INC"},"owners":[{"id":2672,"kind":"person","name":"Melincoff Gwen A","position":1,"cik":"0001614890","reported_name":"Melincoff Gwen A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-24T21:16:05.000Z","date":"2021-05-20","kind":"grant","acquired":true,"shares":9941,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest on May 20, 2022, subject to the director's continued service with the issuer. The restricted stock units will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the issuer, in shares of the issuer's common stock."}],"balance_after":20948,"source":{"system":"sec-edgar","filing":"0001192482-21-000454","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1267565/000119248221000454/edgar.xml","form_type":"4"}},{"id":2909603,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":2672,"kind":"person","name":"Melincoff Gwen A","position":1,"cik":"0001614890","reported_name":"Melincoff Gwen A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee stock option (right to buy)","published_at":"2021-01-13T02:20:14.000Z","date":"2021-01-08","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One hundred percent (100%) of the shares subject to the Option shall be deemed vested on the Transaction Date (which is January 8, 2021)."}],"balance_after":81887,"derivative":{"exercise_price":2.24,"expiration_date":"2031-01-08","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0000899243-21-001699","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1484565/000089924321001699/doc4.xml","form_type":"4"}},{"id":3136887,"issuer":{"id":5169,"kind":"organization","name":"COLLEGIUM PHARMACEUTICAL, INC"},"owners":[{"id":2672,"kind":"person","name":"Melincoff Gwen A","position":1,"cik":"0001614890","reported_name":"Melincoff Gwen A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Purchase)","published_at":"2020-05-22T20:21:41.000Z","date":"2020-05-20","kind":"grant","acquired":true,"shares":8095,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests and becomes exercisable on May 20, 2021, subject to the director's continued service with the issuer."}],"balance_after":8095,"derivative":{"exercise_price":22.05,"expiration_date":"2030-05-20","underlying":"Common Stock","underlying_shares":8095},"source":{"system":"sec-edgar","filing":"0001192482-20-000362","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1267565/000119248220000362/edgar.xml","form_type":"4"}},{"id":3136886,"issuer":{"id":5169,"kind":"organization","name":"COLLEGIUM PHARMACEUTICAL, INC"},"owners":[{"id":2672,"kind":"person","name":"Melincoff Gwen A","position":1,"cik":"0001614890","reported_name":"Melincoff Gwen A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-22T20:21:41.000Z","date":"2020-05-20","kind":"grant","acquired":true,"shares":4047,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest on May 20, 2021, subject to the director's continued service with the issuer. The restricted stock units will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the issuer, in shares of the issuer's common stock."}],"balance_after":11007,"source":{"system":"sec-edgar","filing":"0001192482-20-000362","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1267565/000119248220000362/edgar.xml","form_type":"4"}},{"id":3140780,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":2672,"kind":"person","name":"Melincoff Gwen A","position":1,"cik":"0001614890","reported_name":"Melincoff Gwen A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee stock option (right to buy)","published_at":"2020-05-20T21:56:33.000Z","date":"2020-05-18","kind":"grant","acquired":true,"shares":9530,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One hundred percent (100%) of the shares subject to the Option shall vest on the one year anniversary of the Transaction Date (which is May 18, 2020) or the day before the 2020 Annual Shareholder Meeting, whichever is earlier."}],"balance_after":9530,"derivative":{"exercise_price":3.41,"expiration_date":"2030-05-18","underlying":"Common Stock","underlying_shares":9530},"source":{"system":"sec-edgar","filing":"0000899243-20-013725","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1484565/000089924320013725/doc4.xml","form_type":"4"}},{"id":3305486,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2672,"kind":"person","name":"Melincoff Gwen A","position":1,"cik":"0001614890","reported_name":"Melincoff Gwen A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2020-01-22T22:01:51.000Z","date":"2020-01-20","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant.  The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., 2006 Stock Incentive Plan, as amended."}],"balance_after":40000,"derivative":{"exercise_price":3.55,"expiration_date":"2030-01-20","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001104659-20-005965","document":"tm205452-1_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000110465920005965/tm205452-1_4.xml","form_type":"4"}},{"id":3364151,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":2672,"kind":"person","name":"Melincoff Gwen A","position":1,"cik":"0001614890","reported_name":"Melincoff Gwen A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-11-20T22:02:46.000Z","date":"2019-11-19","kind":"purchase","acquired":true,"shares":10000,"price":1.5364,"value":15364.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $1.5299 to $1.54. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0000899243-19-027705","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1484565/000089924319027705/doc4.xml","form_type":"4"}},{"id":3492687,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":2672,"kind":"person","name":"Melincoff Gwen A","position":1,"cik":"0001614890","reported_name":"Melincoff Gwen A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee stock option (right to buy)","published_at":"2019-06-12T21:37:07.000Z","date":"2019-06-10","kind":"grant","acquired":true,"shares":13000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One hundred percent (100%) of the shares subject to the Option shall vest on the one year anniversary of the Transaction Date (which is June 10, 2019) or the day before the 2019 Annual Shareholder Meeting, whichever is earlier."}],"balance_after":13000,"derivative":{"exercise_price":2.5,"expiration_date":"2029-06-10","underlying":"Common Stock","underlying_shares":13000},"source":{"system":"sec-edgar","filing":"0000899243-19-016668","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1484565/000089924319016668/doc4.xml","form_type":"4"}},{"id":3546542,"issuer":{"id":5169,"kind":"organization","name":"COLLEGIUM PHARMACEUTICAL, INC"},"owners":[{"id":2672,"kind":"person","name":"Melincoff Gwen A","position":1,"cik":"0001614890","reported_name":"Melincoff Gwen A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Purchase)","published_at":"2019-04-29T22:39:25.000Z","date":"2019-04-25","kind":"grant","acquired":true,"shares":9414,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests and becomes exercisable on April 25, 2020, subject to the director's continued service with the issuer."}],"balance_after":9414,"derivative":{"exercise_price":14.57,"expiration_date":"2029-04-25","underlying":"Common Stock","underlying_shares":9414},"source":{"system":"sec-edgar","filing":"0001192482-19-000209","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1267565/000119248219000209/edgar.xml","form_type":"4"}},{"id":3546541,"issuer":{"id":5169,"kind":"organization","name":"COLLEGIUM PHARMACEUTICAL, INC"},"owners":[{"id":2672,"kind":"person","name":"Melincoff Gwen A","position":1,"cik":"0001614890","reported_name":"Melincoff Gwen A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-04-29T22:39:25.000Z","date":"2019-04-25","kind":"grant","acquired":true,"shares":4707,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest on April 25, 2020, subject to the director's continued service with the issuer. The restricted stock units will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the issuer, in shares of the issuer's common stock."}],"balance_after":6960,"source":{"system":"sec-edgar","filing":"0001192482-19-000209","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1267565/000119248219000209/edgar.xml","form_type":"4"}},{"id":3546623,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":2672,"kind":"person","name":"Melincoff Gwen A","position":1,"cik":"0001614890","reported_name":"Melincoff Gwen A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2019-04-29T15:22:35.000Z","date":"2019-04-26","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/48th of the shares on May 26, 2019 and each one-month anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":20000,"derivative":{"exercise_price":1.98,"expiration_date":"2029-04-26","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-19-026336","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1484565/000120919119026336/doc4.xml","form_type":"4"}},{"id":3915229,"issuer":{"id":5169,"kind":"organization","name":"COLLEGIUM PHARMACEUTICAL, INC"},"owners":[{"id":2672,"kind":"person","name":"Melincoff Gwen A","position":1,"cik":"0001614890","reported_name":"Melincoff Gwen A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Purchase)","published_at":"2018-05-29T21:06:51.000Z","date":"2018-05-24","kind":"grant","acquired":true,"shares":4506,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests and becomes exercisable on May 24, 2019, subject to the director's continued service with the issuer."}],"balance_after":4506,"derivative":{"exercise_price":24.95,"expiration_date":"2028-05-24","underlying":"Common Stock","underlying_shares":4506},"source":{"system":"sec-edgar","filing":"0001192482-18-000254","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1267565/000119248218000254/edgar.xml","form_type":"4"}},{"id":3915228,"issuer":{"id":5169,"kind":"organization","name":"COLLEGIUM PHARMACEUTICAL, INC"},"owners":[{"id":2672,"kind":"person","name":"Melincoff Gwen A","position":1,"cik":"0001614890","reported_name":"Melincoff Gwen A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-05-29T21:06:51.000Z","date":"2018-05-24","kind":"grant","acquired":true,"shares":2253,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest on May 24, 2019, subject to the director's continued service with the issuer. The restricted stock units will be settled on such date in shares of the issuer's common stock."}],"balance_after":2253,"source":{"system":"sec-edgar","filing":"0001192482-18-000254","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1267565/000119248218000254/edgar.xml","form_type":"4"}},{"id":4236415,"issuer":{"id":5169,"kind":"organization","name":"COLLEGIUM PHARMACEUTICAL, INC"},"owners":[{"id":2672,"kind":"person","name":"Melincoff Gwen A","position":1,"cik":"0001614890","reported_name":"Melincoff Gwen A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Purchase)","published_at":"2017-08-11T21:37:50.000Z","date":"2017-08-09","kind":"grant","acquired":true,"shares":25067,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable on August 9, 2018, subject to the director's continued service with the issuer."}],"balance_after":25067,"derivative":{"exercise_price":9.89,"expiration_date":"2027-08-09","underlying":"Common Stock","underlying_shares":25067},"source":{"system":"sec-edgar","filing":"0001192482-17-000227","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1267565/000119248217000227/edgar.xml","form_type":"4"}},{"id":4567459,"issuer":{"id":181299,"kind":"organization","name":"Tobira Therapeutics, Inc.","symbol":"TBRA"},"owners":[{"id":2672,"kind":"person","name":"Melincoff Gwen A","position":1,"cik":"0001614890","reported_name":"Melincoff Gwen A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2016-11-03T14:35:28.000Z","date":"2016-11-01","kind":"disposition_to_issuer","acquired":false,"shares":17778,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. (\"Parent\") and Sapphire Acquisition Corp. (\"Purchaser\"), pursuant to which Purchaser was merged with and into Issuer (the \"Merger\"), each option to purchase shares (a \"Company Option\") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the \"Shares\") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the \"Closing Amount\") (each, an \"In the Money Option\"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the \"Effective Time\")"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an \"Out of the Money Option\"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement (\"CVR Agreement\") on or prior to the fifth anniversary of the Effective Time (each such date, a \"Valuation Point\"),"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. (\"Parent\") and Sapphire Acquisition Corp. (\"Purchaser\"), pursuant to which Purchaser was merged with and into Issuer (the \"Merger\"), each option to purchase shares (a \"Company Option\") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the \"Shares\") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the \"Closing Amount\") (each, an \"In the Money Option\"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the \"Effective Time\")"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an \"Out of the Money Option\"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement (\"CVR Agreement\") on or prior to the fifth anniversary of the Effective Time (each such date, a \"Valuation Point\"),"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Shares subject to this option were fully vested immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":7.91,"expiration_date":"2026-01-12","underlying":"Common Stock","underlying_shares":17778},"source":{"system":"sec-edgar","filing":"0001209191-16-148110","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1311596/000120919116148110/doc4.xml","form_type":"4"}},{"id":4567458,"issuer":{"id":181299,"kind":"organization","name":"Tobira Therapeutics, Inc.","symbol":"TBRA"},"owners":[{"id":2672,"kind":"person","name":"Melincoff Gwen A","position":1,"cik":"0001614890","reported_name":"Melincoff Gwen A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2016-11-03T14:35:28.000Z","date":"2016-11-01","kind":"disposition_to_issuer","acquired":false,"shares":15500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. (\"Parent\") and Sapphire Acquisition Corp. (\"Purchaser\"), pursuant to which Purchaser was merged with and into Issuer (the \"Merger\"), each option to purchase shares (a \"Company Option\") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the \"Shares\") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the \"Closing Amount\") (each, an \"In the Money Option\"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the \"Effective Time\")"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an \"Out of the Money Option\"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement (\"CVR Agreement\") on or prior to the fifth anniversary of the Effective Time (each such date, a \"Valuation Point\"),"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. (\"Parent\") and Sapphire Acquisition Corp. (\"Purchaser\"), pursuant to which Purchaser was merged with and into Issuer (the \"Merger\"), each option to purchase shares (a \"Company Option\") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the \"Shares\") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the \"Closing Amount\") (each, an \"In the Money Option\"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the \"Effective Time\")"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an \"Out of the Money Option\"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement (\"CVR Agreement\") on or prior to the fifth anniversary of the Effective Time (each such date, a \"Valuation Point\"),"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Shares subject to this option were fully vested immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":16.52,"expiration_date":"2025-07-08","underlying":"Common Stock","underlying_shares":15500},"source":{"system":"sec-edgar","filing":"0001209191-16-148110","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1311596/000120919116148110/doc4.xml","form_type":"4"}},{"id":4567457,"issuer":{"id":181299,"kind":"organization","name":"Tobira Therapeutics, Inc.","symbol":"TBRA"},"owners":[{"id":2672,"kind":"person","name":"Melincoff Gwen A","position":1,"cik":"0001614890","reported_name":"Melincoff Gwen A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2016-11-03T14:35:28.000Z","date":"2016-11-01","kind":"disposition_to_issuer","acquired":false,"shares":13539,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. (\"Parent\") and Sapphire Acquisition Corp. (\"Purchaser\"), pursuant to which Purchaser was merged with and into Issuer (the \"Merger\"), each option to purchase shares (a \"Company Option\") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the \"Shares\") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the \"Closing Amount\") (each, an \"In the Money Option\"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the \"Effective Time\")"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an \"Out of the Money Option\"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement (\"CVR Agreement\") on or prior to the fifth anniversary of the Effective Time (each such date, a \"Valuation Point\"),"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. (\"Parent\") and Sapphire Acquisition Corp. (\"Purchaser\"), pursuant to which Purchaser was merged with and into Issuer (the \"Merger\"), each option to purchase shares (a \"Company Option\") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the \"Shares\") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the \"Closing Amount\") (each, an \"In the Money Option\"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the \"Effective Time\")"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an \"Out of the Money Option\"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement (\"CVR Agreement\") on or prior to the fifth anniversary of the Effective Time (each such date, a \"Valuation Point\"),"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Shares subject to this option were fully vested immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":8.13,"expiration_date":"2024-06-08","underlying":"Common Stock","underlying_shares":13539},"source":{"system":"sec-edgar","filing":"0001209191-16-148110","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1311596/000120919116148110/doc4.xml","form_type":"4"}}]}